Pulse Biosciences has announced a collaboration with CardioNXT, to support the company’s planned nanosecond pulsed field ablation (nsPFA) cardiac catheter first-in-human study focused on the treatment of atrial fibrillation (AF).
“We are excited to announce this collaboration and the progress we have made integrating our circumferential nsPFA catheter with the CardioNXT iMap System,” said Kevin Danahy, chief executive officer of Pulse Biosciences. “The CardioNXT navigation and mapping system was our top choice for integration with our novel nsPFA cardiac circumferential catheter. Their iMap system offers dynamic referencing to provide superior accuracy and stability when navigating our catheter to targeted tissue areas. We are on track to initiate our first-in-human study in the first half of next year and believe this combination has the potential to achieve best-in-class clinical outcomes.”
The collaboration will include full integration of Pulse Biosciences’ nsPFA circumferential cardiac catheter and CardioNXT’s iMap navigation and mapping system, enabling electrophysiologists to successfully visualise individual cardiac structures and place the nsPFA catheter for circumferential ablations of targeted pulmonary veins in the treatment of atrial fibrillation.
“We are excited to partner with Pulse Biosciences to advance our shared mission of improving cardiac therapy while further demonstrating the versatility of iMap. Pulse’s nsPFA technology provides a highly differentiated catheter-based solution and the integration with our system has the potential to provide fast, accurate, effective, and safe zero-fluoro ablation of cardiac tissue for the treatment of AF,” said Jerome Edwards, chief executive officer of CardioNXT.
